The T-cell biotech Immatics is looking to make some changes to its pipeline.
Immatics released its 2022 financial
results
on Tuesday and announced that it’s planning to discontinue its program for IMA201, an experimental cell therapy for solid tumors that express the antigens known as MAGE4/8. It plans to shift focus to IMA401, a TCR bispecific which goes after the same target.
The German-based biotech said it will treat the remaining patients enrolled in the program before the discontinuation. No other reasons were given for the discontinuation.
Endpoints News
reached out to Immatics for more details but did not receive a response by press time.